JP2007533733A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007533733A5 JP2007533733A5 JP2007509061A JP2007509061A JP2007533733A5 JP 2007533733 A5 JP2007533733 A5 JP 2007533733A5 JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007509061 A JP2007509061 A JP 2007509061A JP 2007533733 A5 JP2007533733 A5 JP 2007533733A5
- Authority
- JP
- Japan
- Prior art keywords
- drug
- betahistine
- pharmaceutical composition
- medicament
- antipsychotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 21
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N Betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 claims 12
- 229940079593 drugs Drugs 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 229960004536 BETAHISTINE Drugs 0.000 claims 9
- 239000004089 psychotropic agent Substances 0.000 claims 9
- 230000000561 anti-psychotic Effects 0.000 claims 8
- XPQIPUZPSLAZDV-UHFFFAOYSA-N 2-Pyridylethylamine Chemical group NCCC1=CC=CC=N1 XPQIPUZPSLAZDV-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 239000011780 sodium chloride Substances 0.000 claims 6
- 230000004584 weight gain Effects 0.000 claims 6
- 235000019786 weight gain Nutrition 0.000 claims 6
- KVWDHTXUZHCGIO-UHFFFAOYSA-N Olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 229960005017 olanzapine Drugs 0.000 claims 4
- 208000008589 Obesity Diseases 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N nicotinic acid Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims 2
- 239000005022 packaging material Substances 0.000 claims 2
- 229940001470 psychoactive drugs Drugs 0.000 claims 2
- 239000003270 steroid hormone Substances 0.000 claims 2
- 229940096699 Bile acid sequestrants Drugs 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 206010033307 Overweight Diseases 0.000 claims 1
- 206010040984 Sleep disease Diseases 0.000 claims 1
- 229920000080 bile acid sequestrant Polymers 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 230000001906 cholesterol absorption Effects 0.000 claims 1
- 235000005686 eating Nutrition 0.000 claims 1
- 235000012631 food intake Nutrition 0.000 claims 1
- 230000037406 food intake Effects 0.000 claims 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000002207 metabolite Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960003512 nicotinic acid Drugs 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 235000020830 overeating Nutrition 0.000 claims 1
- 235000020825 overweight Nutrition 0.000 claims 1
- 229940096700 plain lipid modifying drugs Fibrates Drugs 0.000 claims 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 claims 1
- 230000001105 regulatory Effects 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Claims (25)
- 医薬の製造のための、ベタヒスチン、ベタヒスチンの医薬的に許容され得る塩、および2−(2−アミノエチル)ピリジンであるベタヒスチン代謝産物からなる群から選択されるH1アゴニストの使用方法であって、前記医薬が以下からなる群から選択される少なくとも一つの状態を有するヒト対象を処置するためのものである使用方法:
過食、異常なまでの摂食および/または強迫性摂食、過体重、肥満、糖尿病、睡眠障害、変形性関節炎;および
薬物処置に関連する体重増加。 - 前記医薬は、経口投与のために製造される請求項1に記載の使用方法。
- 前記医薬は、対象の食物摂取を制限することなく、対象の、約1パーセントから約5パーセントに及ぶ体重減少が達成されるように投与される請求項1に記載の使用方法。
- 前記薬物は、ステロイドホルモンおよび精神活性薬物からなる群から選択される請求項1に記載の使用方法。
- 前記H1アゴニストは、医薬的に許容され得るキャリアをさらに含む医薬組成物の一部を形成する請求項1に記載の使用方法。
- 前記医薬は、体重規制剤をさらに含む請求項1に記載の使用方法。
- 前記医薬は、フィブラート系薬剤、HMG−CoAレダクターゼ阻害剤、胆汁酸封鎖剤、コレステロール吸収阻害剤、ニコチン酸、その誘導体、アナログおよび代謝産物、ならびに、それらの任意の混合物からなる群から選択されるさらなる活性な薬剤をさらに含む請求項1に記載の使用方法。
- 前記精神活性薬物が抗精神病薬である請求項4に記載の使用方法。
- 前記抗精神病薬がオランザピンである請求項8に記載の使用方法。
- ヒト対象において肥満を処置するための医薬の製造のためのベタヒスチンまたはその医薬的に許容され得る塩の使用方法。
- ヒト対象において肥満を処置するための医薬の製造のための2−(2−アミノエチル)ピリジンの使用方法。
- ベタヒスチン、ベタヒスチンの医薬的に許容され得る塩、および2−(2−アミノエチル)ピリジンであるベタヒスチン代謝産物からなる群から選択されるH1アゴニストおよび体重増加に関連する薬物を含む医薬組成物。
- ベタヒスチンまたはその医薬的に許容され得る塩、および体重増加に関連する薬物を含む医薬組成物。
- 2−(2−アミノエチル)ピリジンおよび体重増加に関連する薬物を含む医薬組成物。
- 前記薬物は、ステロイドホルモンおよび精神活性薬物からなる群から選択される請求項12〜14のいずれか一項に記載の医薬組成物。
- 前記精神活性薬物が抗精神病薬である請求項15に記載の医薬組成物。
- 前記抗精神病薬がオランザピンである請求項16に記載の医薬組成物。
- 薬物処置に関連する体重増加を減少するまたは防止しながらも、薬物で処置することが有益である医学的状態の処置において使用するために、包装材料中に包装され、前記包装材料中またはその上に印刷して識別されている請求項12〜14のいずれか一項に記載の医薬組成物。
- ベタヒスチンまたはその医薬的に許容され得る塩、および精神活性薬物を含む医薬組成物。
- 2−(2−アミノエチル)ピリジンおよび精神活性薬物を含む医薬組成物。
- 前記精神活性薬物が抗精神病薬である請求項19および20のいずれか一項に記載の医薬組成物。
- 前記抗精神病薬がオランザピンである請求項21に記載の医薬組成物。
- 精神活性薬物に関連する体重増加を減少するための医薬の製造のための、ベタヒスチン、ベタヒスチンの医薬的に許容され得る塩、および2−(2−アミノエチル)ピリジンであるベタヒスチン代謝産物からなる群から選択されるH1アゴニストの使用方法。
- 前記精神活性薬物が抗精神病薬である請求項23に記載の使用方法。
- 前記抗精神病薬がオランザピンである請求項24に記載の使用方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL16159504A IL161595A0 (en) | 2004-04-22 | 2004-04-22 | Betahistine as a weight management agent |
US67029005P | 2005-04-12 | 2005-04-12 | |
PCT/IL2005/000440 WO2005101979A2 (en) | 2004-04-22 | 2005-04-21 | Method of food intake management |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2007533733A JP2007533733A (ja) | 2007-11-22 |
JP2007533733A5 true JP2007533733A5 (ja) | 2008-05-29 |
Family
ID=35197421
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007509061A Pending JP2007533733A (ja) | 2004-04-22 | 2005-04-21 | 食物摂取管理の方法 |
Country Status (10)
Country | Link |
---|---|
US (5) | US20060084686A1 (ja) |
EP (1) | EP1737454A4 (ja) |
JP (1) | JP2007533733A (ja) |
KR (1) | KR20060134041A (ja) |
BR (1) | BRPI0506807A (ja) |
CA (1) | CA2553309A1 (ja) |
EA (1) | EA200601414A1 (ja) |
IL (1) | IL176793A0 (ja) |
NO (1) | NO20063221L (ja) |
WO (1) | WO2005101979A2 (ja) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0506807A (pt) * | 2004-04-22 | 2007-05-29 | Mor Research Applic Ltd | método de gerenciamento de consumo de alimento e composição farmacológica |
US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
US20080051440A1 (en) * | 2004-04-22 | 2008-02-28 | Mor Research Applications Ltd. | Compositions for weight management |
WO2007020079A2 (en) * | 2005-08-17 | 2007-02-22 | Synthon B.V. | Orally disintegratable simvastatin tablets |
US8242148B2 (en) * | 2005-12-23 | 2012-08-14 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
CN101472571B (zh) * | 2006-06-16 | 2012-11-14 | 泰拉科斯有限公司 | 毒蕈碱型受体m1拮抗剂在制备治疗心理学病况药物中的应用 |
US8748419B2 (en) * | 2006-06-16 | 2014-06-10 | Theracos, Inc. | Treating obesity with muscarinic receptor M1 antagonists |
US20080033019A1 (en) * | 2006-08-07 | 2008-02-07 | Duke University | Cholesterol lowering drug combination |
EP3788877A1 (en) * | 2007-04-11 | 2021-03-10 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
WO2008157094A1 (en) * | 2007-06-13 | 2008-12-24 | Cypress Bioscience, Inc. | Improving the tolerability of mirtazapine and a second active by using them in combination |
WO2008156707A1 (en) | 2007-06-15 | 2008-12-24 | University Of Florida Research Foundation | Therapeutic compounds |
DK2293794T3 (da) | 2008-05-27 | 2013-08-19 | Univ Melbourne | Fremgangsmåde til behandling af pattedyr med dysfunktioner af det eustakiske rør |
WO2011009012A1 (en) * | 2009-07-15 | 2011-01-20 | Columbia University | METHODS OF SUPPRESSING APPETITE BY THE ADMINISTRATION OF ANTAGONISTS OF THE SEROTONIN HTR1a or HTR2b RECEPTORS OR INHIBITORS OF TPH2 |
US20110021507A1 (en) * | 2009-07-22 | 2011-01-27 | Theracos, Inc. | Inhibiting antipsychotic-induced weight gain |
BR112012011561A2 (pt) * | 2009-10-13 | 2017-01-10 | Nestec Sa | sistemas para avaliação da ingestão dietética e métodos de uso do mesmo |
AU2010326676B2 (en) | 2009-12-04 | 2013-03-14 | Alkermes Pharma Ireland Limited | Morphinan derivatives for the treatment of drug overdose |
US20110143704A1 (en) | 2009-12-14 | 2011-06-16 | William Lorentz | Specialized dial a chip |
HRP20240109T1 (hr) * | 2010-08-23 | 2024-03-29 | Alkermes Pharma Ireland Limited | Postupci za liječenje povećanja tjelesne težine induciranog antipsihoticima |
US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
US20140072935A1 (en) * | 2012-09-07 | 2014-03-13 | Tina M. Herron | Method of Regulating Caloric Intake |
WO2014190270A1 (en) | 2013-05-24 | 2014-11-27 | Alkermes Pharma Ireland Limited | Morphan and morphinan analogues, and methods of use |
WO2014190271A2 (en) | 2013-05-24 | 2014-11-27 | Alkermes Pharma Ireland Limted | Methods for treating depressive symptoms |
RU2540911C2 (ru) * | 2013-06-11 | 2015-02-10 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Воронежская государственная медицинская академия им. Н.Н. Бурденко" Министерства здравоохранения Российской Федерации | Способ коррекции синдрома ночной еды у пациентов с тревожно-депрессивными расстройствами |
DE102015202695A1 (de) * | 2015-02-13 | 2016-08-18 | Carl Zeiss Smt Gmbh | Prüfvorrichtung sowie Verfahren zum Prüfen eines Spiegels |
RS60554B1 (sr) | 2017-02-02 | 2020-08-31 | Otolanum Ag | Intranazalna kompozicija koja sadrži betahistin |
WO2022101444A1 (en) | 2020-11-12 | 2022-05-19 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1577871A (en) * | 1976-05-28 | 1980-10-29 | Unimed Inc | Prevention of myocardial infarction |
JPS55154915A (en) * | 1979-05-21 | 1980-12-02 | Jiyan Sadeia Shieruki | Medicine mold |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
DE69939027D1 (de) | 1998-12-23 | 2008-08-14 | Maxim Pharm Inc | Synthese von histamin-dihydrochlorid |
NZ512532A (en) | 1998-12-23 | 2003-12-19 | G | Combinations for treating cardiovascular diseases like hypercholesterolemia and atherosclerosis |
IT1309591B1 (it) | 1999-03-05 | 2002-01-24 | Formenti Farmaceutici Spa | Composizioni a rilascio controllato di betaistina. |
CA2363784A1 (en) * | 1999-05-19 | 2000-11-30 | Astrazeneca Ab | Method of treatment |
EE200200504A (et) * | 2000-03-08 | 2004-02-16 | Awd.Pharma Gmbh & Co. Kg | Farmatseutilised preparaadid |
US6607748B1 (en) * | 2000-06-29 | 2003-08-19 | Vincent Lenaerts | Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture |
US20030064967A1 (en) | 2001-04-11 | 2003-04-03 | Jayraz Luchoomun | Methods to increase plasma HDL cholesterol levels and improve HDL functionality with probucol monoesters |
US20030162824A1 (en) | 2001-11-12 | 2003-08-28 | Krul Elaine S. | Methods of treating or preventing a cardiovascular condition using a cyclooxygenase-1 inhibitor |
US20040110803A1 (en) | 2002-09-13 | 2004-06-10 | Hossein Dovlatabadi | Methods and compositions for the use of D-malic acid to decrease serum triglyceride, cholesterol and lipoprotein levels |
US20050222175A1 (en) | 2004-03-31 | 2005-10-06 | Dhanoa Dale S | New piperidinylamino-thieno[2,3-D] pyrimidine compounds |
US20080051440A1 (en) * | 2004-04-22 | 2008-02-28 | Mor Research Applications Ltd. | Compositions for weight management |
US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
BRPI0506807A (pt) * | 2004-04-22 | 2007-05-29 | Mor Research Applic Ltd | método de gerenciamento de consumo de alimento e composição farmacológica |
WO2006023702A2 (en) | 2004-08-20 | 2006-03-02 | Cypress Bioscience, Inc. | Method for treating sleep related breathing disorders with setiptiline |
-
2005
- 2005-04-21 BR BRPI0506807-0A patent/BRPI0506807A/pt not_active IP Right Cessation
- 2005-04-21 WO PCT/IL2005/000440 patent/WO2005101979A2/en not_active Application Discontinuation
- 2005-04-21 EA EA200601414A patent/EA200601414A1/ru unknown
- 2005-04-21 JP JP2007509061A patent/JP2007533733A/ja active Pending
- 2005-04-21 KR KR1020067015532A patent/KR20060134041A/ko not_active Application Discontinuation
- 2005-04-21 EP EP05734836A patent/EP1737454A4/en not_active Withdrawn
- 2005-04-21 CA CA002553309A patent/CA2553309A1/en not_active Abandoned
- 2005-11-22 US US11/283,865 patent/US20060084686A1/en not_active Abandoned
- 2005-11-22 US US11/283,928 patent/US7737165B2/en active Active
-
2006
- 2006-07-11 IL IL176793A patent/IL176793A0/en unknown
- 2006-07-11 NO NO20063221A patent/NO20063221L/no not_active Application Discontinuation
-
2007
- 2007-08-03 US US11/882,677 patent/US20080004324A1/en not_active Abandoned
- 2007-08-03 US US11/882,740 patent/US20080004322A1/en not_active Abandoned
- 2007-08-03 US US11/882,678 patent/US20080051439A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2007533733A5 (ja) | ||
Cilurzo et al. | Orodispersible dosage forms: Biopharmaceutical improvements and regulatory requirements | |
RU2355387C2 (ru) | Трансдермальный гранисетрон | |
JP2008007519A5 (ja) | ||
CA2450366A1 (en) | Controlled heat induced rapid delivery of pharmaceuticals from skin depot | |
US20090149518A1 (en) | Pharmaceutical for protection of motor nerve in patient with amyotrophic lateral sclerosis | |
CN101102771A (zh) | 用免疫调节化合物治疗和控制中枢神经系统损伤的方法和组合物 | |
WO2005117803A1 (ja) | 塊状物質含有積層フィルム状の可食性口腔内投与剤の製造方法および塊状物質含有積層フィルム状の可食性口腔内投与剤 | |
JP2010530431A5 (ja) | ||
ES2762113T3 (es) | Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor | |
JP2010540519A5 (ja) | ||
TW201136916A (en) | New uses | |
JP2021509114A (ja) | Pde v阻害剤のための液体経口処方物 | |
AU2017379247A1 (en) | Pharmaceutical dosage forms containing TASK-1 and TASK-3 channel inhibitors, and the use of same in breathing disorder therapy | |
TW200924745A (en) | Organic compounds | |
JP2009506043A5 (ja) | ||
WO2006116470A1 (en) | Use of metformin to counteract weight gain associated with aripiprazole or ziprasidone treatment | |
US20200093737A1 (en) | Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy | |
WO2013173317A1 (en) | TREATMENT OF OBSTRUCTIVE SLEEP APNEA WITH α2-ADRENERGIC RECEPTOR AGONISTS | |
EP1772149A1 (en) | Drug for prevention or treatment of diabetes | |
JP2005511120A (ja) | 皮膚デポからの医薬品の制御された熱誘導迅速送達 | |
Hassan | Dexmedetomidine versus ketofol for moderate sedation in Endoscopic Retrograde Cholangiopancreatography (ERCP) comparative study | |
US20160287549A1 (en) | Novel methods for treating neurodegenerative diseases | |
Frijlink | Benefits of different drug formulations in psychopharmacology | |
JP2009539877A5 (ja) |